Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
-
REGULATORY FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
-
BUSINESS Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
-
REGULATORY Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
-
ACADEMIA Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
-
BUSINESS Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
-
REGULATORY Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
-
ACADEMIA Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
-
REGULATORY No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
-
BUSINESS AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
-
REGULATORY PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
-
BUSINESS Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
-
ACADEMIA New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
-
BUSINESS Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
-
BUSINESS Drug Makers Invest in Developing AD Treatments
December 10, 2013
-
BUSINESS Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
-
REGULATORY FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
-
BUSINESS “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End
December 9, 2013
-
BUSINESS Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
-
BUSINESS Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…